1.           Introduction

1.1       The Insight Partners Research Report Guidance

1.2       Market Segmentation

2.           Europe Biosimilars Market – Key Takeaways

3.       Research Methodology

3.1       Coverage

3.2       Secondary Research

3.3       Primary Research

4.           Europe Biosimilars Market – Market Landscape

4.1       Overview

4.1.1         Europe PEST Analysis

4.2       Actual Market Price/Net Price

4.2.1         France

4.2.2         Germany

4.2.3         Italy

4.2.4         Spain

4.2.5         UK

5.           Europe Biosimilars Market

5.1       Market Drivers

5.1.1         Increasing Prevalence of Chronic Diseases

5.1.2         Rising Approvals of Biosimilars

5.2       Market Restraints

5.2.1         High Cost Involvement and Complexities in Biosimilar Product Manufacturing

5.3       Market Opportunities

5.3.1         Patent Expiry of Blockbuster Biologics

5.4       Future Trends

5.4.1         Collaborations for Biosimilars and Clinical Trials

5.5       Impact analysis

6.           Europe Biosimilars Market – Regional Analysis

6.1       Europe Biosimilars Market Revenue Forecast and Analysis

7.           Europe Biosimilars Market – Revenue and Forecast to 2030 – by Disease Indication

7.1       Overview

7.2       Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)

7.3       Cancer

7.3.1         Overview

7.3.2         Cancer: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

7.4       Diabetes

7.4.1         Overview

7.4.2         Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

7.5       Autoimmune Diseases

7.5.1         Overview

7.5.2         Autoimmune Diseases: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

7.5.3         Psoriasis

7.5.3.1            Overview

7.5.4         Psoriasis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

7.5.5         Arthritis

7.5.5.1            Overview

7.5.6         Arthritis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

7.5.7         Others

7.5.7.1            Overview

7.5.7.2            Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

7.6       Other Disease Indication

7.6.1         Overview

7.6.2         Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

8.           Europe Biosimilars Market Analysis and Forecasts to 2028 – by Route of Administration

8.1       Overview

8.2       Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)

8.3       Intravenous

8.3.1         Overview

8.3.2         Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

8.4       Subcutaneous

8.4.1         Overview

8.4.2         Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

8.5       Others

8.5.1         Overview

8.5.2         Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

9.           Europe Biosimilars Market – Revenue and Forecast to 2030 – by Drug Class

9.1       Overview

9.2       Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)

9.3       Granulocyte Colony-Stimulating Factor

9.3.1         Overview

9.3.2         Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

9.4       Insulin

9.4.1         Overview

9.4.2         Insulin: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

9.5       TNF Blockers and Monoclonal Antibodies

9.5.1         Overview

9.5.2         TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

9.6       Others

9.6.1         Overview

9.6.2         Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.        Europe Biosimilars Market – Revenue and Forecast to 2030 – by Distribution Channel

10.1     Overview

10.2     Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)

10.3     Endocrinologists

10.3.1       Overview

10.4     Immunologists

10.4.1       Overview

10.5     Rheumatologists

10.5.1       Overview

10.6     Oncologists

10.6.1       Overview

10.7     Dermatologists

10.7.1       Overview

10.8     Retina Compounding

10.8.1       Overview

10.9     Others

10.9.1       Overview

10.10  Hospital Pharmacies

10.10.1    Overview

10.10.2    Hospital Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.10.3    Endocrinologists

10.10.3.1       Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.10.4    Immunologists

10.10.4.1       Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.10.5    Rheumatologists

10.10.5.1       Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.10.6    Oncologists

10.10.6.1       Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.10.7    Dermatologists

10.10.7.1       Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.10.8    Retina Specialists

10.10.8.1       Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.10.9    Others

10.10.9.1       Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.11  Compounding Pharmacies

10.11.1    Overview

10.11.2    Compounding Pharmacies : Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.11.3    Endocrinologists

10.11.3.1       Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.11.4    Immunologists

10.11.4.1       Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.11.5    Rheumatologists

10.11.5.1       Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.11.6    Oncologists

10.11.6.1       Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.11.7    Dermatologists

10.11.7.1       Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.11.8    Retina Specialists

10.11.8.1       Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.11.9    Others

10.11.9.1       Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.12  Retail Pharmacies

10.12.1    Overview

10.12.2    Retail Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.12.3    Endocrinologists

10.12.3.1       Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.12.4    Immunologists

10.12.4.1       Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.12.5    Rheumatologists

10.12.5.1       Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.12.6    Oncologists

10.12.6.1       Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.12.7    Dermatologists

10.12.7.1       Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.12.8    Retina Specialists

10.12.8.1       Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.12.9    Others

10.12.9.1       Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.13  Online Pharmacies

10.13.1    Overview

10.13.2    Online Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.13.3    Endocrinologists

10.13.3.1       Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.13.4    Immunologists

10.13.4.1       Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.13.5    Rheumatologists

10.13.5.1       Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.13.6    Oncologists

10.13.6.1       Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.13.7    Dermatologists

10.13.7.1       Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.13.8    Retina Specialists

10.13.8.1       Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.13.9    Others

10.13.9.1       Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

11.        Europe Biosimilars Market – Revenue and Forecast to 2030 – Geographic Analysis

11.1     Europe Biosimilars Market, Revenue and Forecast to 2030

11.1.1       Overview

11.1.2       Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)

11.1.2.1          Europe Biosimilars Market, by Disease Indication

11.1.2.2          Europe Biosimilars Market, by Autoimmune Diseases

11.1.2.3          Europe Biosimilars Market, by Route of Administration

11.1.2.4          Europe Biosimilars Market, by Drug Class

11.1.2.5          Europe Biosimilars Market, by Distribution Channel

11.1.2.6          Europe Biosimilars Market, by Hospital Pharmacies

11.1.2.7          Europe Biosimilars Market, by Compounding Pharmacies

11.1.2.8          Europe Biosimilars Market, by Retail Pharmacies

11.1.2.9          Europe Biosimilars Market, by Online Pharmacies

11.1.2.10       Europe Biosimilars Market by Country

11.1.2.10.1     Germany

11.1.2.10.1.1      Overview

11.1.2.10.1.2      Germany Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)

11.1.2.10.1.2.1    Germany Biosimilars Market, by Disease Indication

11.1.2.10.1.2.2    Germany Biosimilars Market, by Autoimmune Diseases

11.1.2.10.1.2.3    Germany Biosimilars Market, by Route of Administration

11.1.2.10.1.2.4    Germany Biosimilars Market, by Drug Class

11.1.2.10.1.2.5    Germany Biosimilars Market, by Distribution Channel

11.1.2.10.1.2.6    Germany Biosimilars Market, by Hospital Pharmacies

11.1.2.10.1.2.7    Germany Biosimilars Market, by Compounding Pharmacies

11.1.2.10.1.2.8    Germany Biosimilars Market, by Retail Pharmacies

11.1.2.10.1.2.9    Germany Biosimilars Market, by Online Pharmacies

11.1.2.10.2     UK

11.1.2.10.3     Overview

11.1.2.10.3.1      UK Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)

11.1.2.10.3.1.1    UK Biosimilars Market, by Disease Indication

11.1.2.10.3.1.2    UK Biosimilars Market, by Autoimmune Diseases

11.1.2.10.3.1.3    UK Biosimilars Market, by Route of Administration

11.1.2.10.3.1.4    UK Biosimilars Market, by Drug Class

11.1.2.10.3.1.5    UK Biosimilars Market, by Distribution Channel

11.1.2.10.3.1.6    UK Biosimilars Market, by Hospital Pharmacies

11.1.2.10.3.1.7    UK Biosimilars Market, by Compounding Pharmacies

11.1.2.10.3.1.8    UK Biosimilars Market, by Retail Pharmacies

11.1.2.10.3.1.9    UK Biosimilars Market, by Online Pharmacies

11.1.2.10.4     France

11.1.2.10.4.1      Overview

11.1.2.10.4.2      France Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)

11.1.2.10.4.2.1    France Biosimilars Market, by Disease Indication

11.1.2.10.4.2.2    France Biosimilars Market, by Autoimmune Diseases

11.1.2.10.4.2.3    France Biosimilars Market, by Route of Administration

11.1.2.10.4.2.4    France Biosimilars Market, by Drug Class

11.1.2.10.4.2.5    France Biosimilars Market, by Distribution Channel

11.1.2.10.4.2.6    France Biosimilars Market, by Hospital Pharmacies

11.1.2.10.4.2.7    France Biosimilars Market, by Compounding Pharmacies

11.1.2.10.4.2.8    France Biosimilars Market, by Retail Pharmacies

11.1.2.10.4.2.9    France Biosimilars Market, by Online Pharmacies

11.1.2.10.5     Italy

11.1.2.10.5.1      Overview

11.1.2.10.5.2      Italy Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)

11.1.2.10.5.2.1    Italy Biosimilars Market, by Disease Indication

11.1.2.10.5.2.2    Italy Biosimilars Market, by Autoimmune Diseases

11.1.2.10.5.2.3    Italy Biosimilars Market, by Route of Administration

11.1.2.10.5.2.4    Italy Biosimilars Market, by Drug Class

11.1.2.10.5.2.5    Italy Biosimilars Market, by Distribution Channel

11.1.2.10.5.2.6    Italy Biosimilars Market, by Hospital Pharmacies

11.1.2.10.5.2.7    Italy Biosimilars Market, by Compounding Pharmacies

11.1.2.10.5.2.8    Italy Biosimilars Market, by Retail Pharmacies

11.1.2.10.5.2.9    Italy Biosimilars Market, by Online Pharmacies

11.1.2.10.6     Spain

11.1.2.10.6.1      Overview

11.1.2.10.6.2      Spain Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)

11.1.2.10.6.2.1    Spain Biosimilars Market, by Disease Indication

11.1.2.10.6.2.2    Spain Biosimilars Market, by Autoimmune Diseases

11.1.2.10.6.2.3    Spain Biosimilars Market, by Route of Administration

11.1.2.10.6.2.4    Spain Biosimilars Market, by Drug Class

11.1.2.10.6.2.5    Spain Biosimilars Market, by Distribution Channel

11.1.2.10.6.2.6    Spain Biosimilars Market, by Hospital Pharmacies

11.1.2.10.6.2.7    Spain Biosimilars Market, by Compounding Pharmacies

11.1.2.10.6.2.8    Spain Biosimilars Market, by Retail Pharmacies

11.1.2.10.6.2.9    Spain Biosimilars Market, by Online Pharmacies

11.1.2.10.7     Rest of Europe

11.1.2.10.7.1      Overview

11.1.2.10.7.2      Rest of Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)

11.1.2.10.7.2.1    Rest of Europe Biosimilars Market, by Disease Indication

11.1.2.10.7.2.2    Rest of Europe Biosimilars Market, by Autoimmune Diseases

11.1.2.10.7.2.3    Rest of Europe Biosimilars Market, by Route of Administration

11.1.2.10.7.2.4    Rest of Europe Biosimilars Market, by Drug Class

11.1.2.10.7.2.5    Rest of Europe Biosimilars Market, by Distribution Channel

11.1.2.10.7.2.6    Rest of Europe Biosimilars Market, by Hospital Pharmacies

11.1.2.10.7.2.7    Rest of Europe Biosimilars Market, by Compounding Pharmacies

11.1.2.10.7.2.8    Rest of Europe Biosimilars Market, by Retail Pharmacies

11.1.2.10.7.2.9    Rest of Europe Biosimilars Market, by Online Pharmacies

12.        Pre and Post COVID-19 Impact

12.1     Pre and Post COVID-19 Impact

13.        Biosimilars Market – Industry Landscape

13.1     Overview

13.2     Growth Strategies in Biosimilars Market

13.3     Inorganic Growth Strategies

13.3.1       Overview

13.4     Organic Growth Strategies

13.4.1       Overview

14.        Company Profiles

14.1     Amgen Inc

14.1.1       Key Facts

14.1.2       Business Description

14.1.3       Products and Services

14.1.4       Financial Overview

14.1.5       SWOT Analysis

14.1.6       Key Developments

14.2     Celltrion Inc

14.2.1       Key Facts

14.2.2       Business Description

14.2.3       Products and Services

14.2.4       Financial Overview

14.2.5       SWOT Analysis

14.2.6       Key Developments

14.3     Sanofi SA

14.3.1       Key Facts

14.3.2       Business Description

14.3.3       Products and Services

14.3.4       Financial Overview

14.3.5       SWOT Analysis

14.4     Biocon Ltd

14.4.1       Key Facts

14.4.2       Business Description

14.4.3       Products and Services

14.4.4       Financial Overview

14.4.5       SWOT Analysis

14.4.6       Key Developments

14.5     Samsung Bioepis Co Ltd

14.5.1       Key Facts

14.5.2       Business Description

14.5.3       Products and Services

14.5.4       Financial Overview

14.5.5       SWOT Analysis

14.5.6       Key Developments

14.6     Eli Lilly and Co

14.6.1       Key Facts

14.6.2       Business Description

14.6.3       Products and Services

14.6.4       Financial Overview

14.6.5       SWOT Analysis

14.6.6       Key Developments

14.7     Sandoz AG

14.7.1       Key Facts

14.7.2       Business Description

14.7.3       Products and Services

14.7.4       Financial Overview

14.7.5       SWOT Analysis

14.7.6       Key Developments

14.8     Teva Pharmaceutical Industries Ltd

14.8.1       Key Facts

14.8.2       Business Description

14.8.3       Products and Services

14.8.4       Financial Overview

14.8.5       SWOT Analysis

14.8.6       Key Developments

14.9     Pfizer Inc

14.9.1       Key Facts

14.9.2       Business Description

14.9.3       Products and Services

14.9.4       Financial Overview

14.9.5       SWOT Analysis

14.9.6       Key Developments

14.10  Dr. Reddy's Laboratories Ltd

14.10.1    Key Facts

14.10.2    Business Description

14.10.3    Products and Services

14.10.4    Financial Overview

14.10.5    SWOT Analysis

14.10.6    Key Developments

15.        Appendix

15.1     About The Insight Partners

15.2     Glossary of Terms

List of Tables

Table 1.             Comparison Between Different Drug Developments

Table 2.             Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication

Table 3.             Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases

Table 4.             Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration

Table 5.             Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class

Table 6.             Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel

Table 7.             Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies

Table 8.             Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies

Table 9.             Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies

Table 10.          Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies

Table 11.          Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication

Table 12.          Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases

Table 13.          Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration

Table 14.          Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class

Table 15.          Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel

Table 16.          Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies

Table 17.          Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies

Table 18.          Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies

Table 19.          Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies

Table 20.          UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication

Table 21.          UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases

Table 22.          UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration

Table 23.          UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class

Table 24.          UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel

Table 25.          UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies

Table 26.          UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies

Table 27.          UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies

Table 28.          UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies

Table 29.          France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication

Table 30.          France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases

Table 31.          France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration

Table 32.          France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class

Table 33.          France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel

Table 34.          France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies

Table 35.          France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies

Table 36.          France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies

Table 37.          France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies

Table 38.          Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication

Table 39.          Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases

Table 40.          Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration

Table 41.          Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class

Table 42.          Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel

Table 43.          Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies

Table 44.          Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies

Table 45.          Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies

Table 46.          Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies

Table 47.          Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication

Table 48.          Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases

Table 49.          Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration

Table 50.          Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class

Table 51.          Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel

Table 52.          Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies

Table 53.          Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies

Table 54.          Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies

Table 55.          Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies

Table 56.          Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication

Table 57.          Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases

Table 58.          Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration

Table 59.          Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class

Table 60.          Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel

Table 61.          Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies

Table 62.          Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies

Table 63.          Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies

Table 64.          Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies

Table 65.          Recent Inorganic Growth Strategies in the Biosimilars Market

Table 66.          Recent Organic Growth Strategies in Biosimilars Market

Table 67.          Glossary of Terms

List of Figures

Figure 1.           Biosimilars Market Segmentation

Figure 2.           Biosimilars Market, by Region

Figure 3.           Key Insights

Figure 4.           Europe: PEST Analysis

Figure 5.           Europe Biosimilars Market- Key Industry Dynamics

Figure 6.           Europe Biosimilars Market: Impact Analysis of Drivers and Restraints

Figure 7.           Europe Biosimilars Market – Revenue Forecast and Analysis – 2020–2030

Figure 8.           Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)

Figure 9.           Cancer: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 10.        Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 11.        Autoimmune Diseases: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 12.        Psoriasis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 13.        Arthritis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 14.        Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 15.        Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 16.        Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)

Figure 17.        Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 18.        Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 19.        Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 20.        Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)

Figure 21.        Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 22.        Insulin: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 23.        TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 24.        Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 25.        Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)

Figure 26.        Hospital Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 27.        Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 28.        Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 29.        Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 30.        Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 31.        Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 32.        Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 33.        Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 34.        Compounding Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 35.        Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 36.        Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 37.        Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 38.        Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 39.        Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 40.        Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 41.        Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 42.        Retail Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 43.        Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 44.        Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 45.        Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 46.        Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 47.        Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 48.        Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 49.        Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 50.        Online Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 51.        Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 52.        Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 53.        Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 54.        Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 55.        Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 56.        Retina Compounding: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 57.        Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

Figure 58.        Europe Biosimilars Market, By Region, 2022 ($Mn)

Figure 59.        Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)

Figure 60.        Europe Biosimilars Market, By Key Countries, 2022 And 2030 (%)

Figure 61.        Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)

Figure 62.        UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)

Figure 63.        France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)

Figure 64.        Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)

Figure 65.        Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)

Figure 66.        Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)

Figure 67.        Pre and Post COVID-19 Impact on Europe Biosimilars Market

Figure 68.        Growth Strategies in Biosimilars Market